Loading...

Advanced Therapies And European Integration Will Redefine Healthcare Delivery

Published
14 Mar 25
Updated
01 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-14.1%
7D
3.4%

Author's Valuation

€24.548.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 01 May 25

Fair value Increased 3.99%

Shared on 24 Apr 25

Fair value Decreased 4.42%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on 17 Apr 25

AnalystConsensusTarget has increased profit margin from 1.7% to 1.9% and decreased future PE multiple from 25.6x to 22.5x.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.14%

AnalystConsensusTarget has decreased profit margin from 2.3% to 1.7%, increased future PE multiple from 16.4x to 25.6x and increased shares outstanding growth rate from 0.0% to 0.1%.

Shared on 26 Mar 25

Fair value Decreased 4.98%

AnalystConsensusTarget has decreased revenue growth from 4.6% to 3.6%, decreased profit margin from 2.7% to 2.3% and decreased shares outstanding growth rate from 0.1% to 0.0%.

Shared on 19 Mar 25

Fair value Decreased 5.64%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.